Insomnia Therapeutics Market Size 2025-2029
The insomnia therapeutics market size is forecast to increase by USD 1.2 billion at a CAGR of 5.9% between 2024 and 2029.
- The market is experiencing significant growth, driven by the increasing prevalence of insomnia as a health concern. With the global population grappling with the effects of stress, hectic lifestyles, and other factors contributing to sleep disorders, the demand for effective therapeutic solutions is on the rise. This trend is further fueled by the growing recognition of insomnia as a disease, rather than a mere inconvenience. However, the market faces challenges in the form of limited awareness and understanding of insomnia and its impact on overall health. This market is driven by the growing prevalence of sleep disorders, particularly among the geriatric population and those suffering from mental health disorders, anxiety, stress, and sleep irregularity.
- Additionally, the increasing focus on non-pharmacological treatments, such as cognitive behavioral therapy and lifestyle modifications, presents competition for pharmaceutical solutions. Companies in the market must navigate these challenges by raising awareness, offering innovative non-pharmacological solutions, and collaborating with healthcare professionals to ensure effective patient care. By capitalizing on these opportunities and addressing the challenges, market participants can position themselves for success in the rapidly evolving landscape of insomnia therapeutics. Over-the-counter (OTC) drugs and nonpharmacological treatments, such as behavior therapy and sleep schedule adjustments, are also significant contributors to the market.
What will be the Size of the Insomnia Therapeutics Market during the forecast period?
Explore in-depth regional segment analysis with market size data - historical 2019-2023 and forecasts 2025-2029 - in the full report.
Request Free Sample
The market encompasses various sleep disorder classifications and associated interventions. Sleep regulatory mechanisms, such as sleep-wake transition and sleep-wake timing, play a crucial role in the development of sleep disorders. Sleep electroencephalography (EEG) and sleep electrooculography (EOG) are essential sleep medicine technologies for diagnosing sleep disorders, including sleep-related breathing disorders and sleep architecture evaluation and disruption. Sleep promoting substances, like melatonin and benzodiazepines, are commonly used to treat insomnia. Chronic insomnia treatment strategies include sleep intervention strategies, such as cognitive-behavioral therapy and relaxation techniques. Sleep studies, conducted in sleep centers, help diagnose various sleep disorders, including sleep-disordered breathing, obstructive sleep apnea, and central sleep apnea.
Sleepiness severity rating and sleep efficiency index are essential sleep quality metrics for assessing the effectiveness of insomnia treatment guidelines. Sleep neurophysiology research continues to uncover new insights into sleep architecture disruption and sleep continuity disruption, paving the way for innovative sleep disorder therapeutics. Sleep medication comparison is a critical aspect of personalized insomnia treatment, considering the unique needs of each patient. Sleep disorder epidemiology highlights the prevalence and impact of sleep disorders on public health, emphasizing the importance of prevention and early intervention. Digital therapeutics, telehealth, and artificial intelligence are emerging trends in insomnia disorder care.
How is this Insomnia Therapeutics Industry segmented?
The insomnia therapeutics industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.
- Type
- Drug
- Devices
- Distribution Channel
- Prescription
- OTC
- Drug Class
- Non-benzodiazepines
- Benzodiazepines
- Antidepressants
- Orexin receptor antagonists
- Melatonin receptor agonists
- Geography
- North America
- US
- Canada
- Mexico
- Europe
- France
- Germany
- UK
- APAC
- China
- India
- Japan
- South Korea
- Rest of World (ROW)
- North America
By Type Insights
The Drug segment is estimated to witness significant growth during the forecast period. The market encompasses a range of pharmaceutical treatments for sleep disturbances. These therapeutics are categorized into various classes, including sedative-hypnotics, benzodiazepines, non-benzodiazepines, melatonin receptor agonists, orexin receptor antagonists, and other medications. People with diabetes face higher healthcare costs and a two to three times greater risk of cardiovascular diseases and related comorbidities. Sedative-hypnotics, acting as central nervous system depressants, facilitate sleep onset. Barbiturates, such as secobarbital and pentobarbital, are sedative-hypnotics commonly used for insomnia. Benzodiazepines, another class, amplify the effects of the neurotransmitter gamma-aminobutyric acid (GABA), inducing sedation, hypnosis, anxiolysis, and muscle relaxation. Temazepam, lorazepam, and diazepam are benzodiazepines frequently employed for insomnia treatment.
Sleep neurotransmitters, such as serotonin and melatonin, play a crucial role in regulating sleep-wake cycles. Sleep latency measurement and continuity assessment are essential in evaluating treatment progress and patient outcomes. Sleep disorders, such as insomnia, affect millions worldwide, necessitating ongoing research and advancements in sleep medicine. Orexin receptor antagonists and melatonin receptor agonists are among the latest sleep therapeutics, offering potential benefits for patients. The market continues to evolve, focusing on improving sleep efficiency, addressing sleep cycle stages, and addressing the complex interplay between sleep and various health conditions. Smart wearable devices and digital prescription therapy are emerging trends in insomnia treatment, offering personalized insights into sleep patterns and enabling healthcare professionals to monitor and adjust treatment plans accordingly.
The Drug segment was valued at USD 2.54 billion in 2019 and showed a gradual increase during the forecast period.
The Insomnia Therapeutics Market is gaining traction as awareness around sleep disorder prevalence continues to rise globally. Growing research into sleep disturbance causes, ranging from stress and lifestyle to underlying medical condition,s drives demand for targeted sleep disorders treatment. Clinicians increasingly rely on validated sleepiness scales to diagnose severity and personalize therapy. Breakthroughs in sleep medicine advancements, including pharmacological innovations and cognitive behavioral therapies, are reshaping care strategies. Sleep disorders, including sleep onset insomnia and maintenance insomnia, can be treated with these therapeutics. Personalized treatments, such as natural ingredients, generic drugs, and patient rebates, are becoming increasingly important in ensuring accessibility and affordability for patients.
Sleep hygiene techniques and medication are essential for managing sleep deprivation effects, which can lead to cognitive impairment, mood disturbances, and cardiovascular issues. Polysomnography interpretation and sleep study protocols help diagnose sleep disorders, while cognitive behavioral therapy and sleep diary analysis offer non-pharmacological treatment options. Narcolepsy symptom management, circadian rhythm regulation, and sleep architecture analysis are also integral to the market. Restless legs syndrome and sleep architecture changes can lead to sleep fragmentation patterns and disruptions in the sleep-wake cycle. Insomnia medication efficacy, sleep quality improvement, and sleep disorder comorbidities are key factors driving market growth.
Regional Analysis
North America is estimated to contribute 62% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
The market in North America is driven by the high prevalence of sleep disturbances and the increasing awareness of their detrimental health consequences. Prescription pharmaceuticals, including benzodiazepines, non-benzodiazepine receptor agonists, and melatonin receptor agonists, are commonly prescribed to address sleep onset and maintenance insomnia by modulating sleep neurotransmitters and regulating the sleep-wake homeostasis. Over-the-counter (OTC) medications, such as antihistamines and melatonin supplements, are also popular choices for managing sleep disturbances. Sleep hygiene techniques, like maintaining a consistent sleep schedule and creating a restful environment, are essential in treating insomnia. Polysomnography interpretation and sleep study protocols provide valuable insights into the underlying causes of sleep disorders, including sleep latency measurement, sleep fragmentation patterns, and sleep architecture analysis.
Narcolepsy, restless legs syndrome, and circadian rhythm regulation disorders are among the various sleep disorders treated with medication and therapy. Cognitive behavioral therapy, a non-pharmacological approach, has shown efficacy in managing insomnia by addressing sleep-related thoughts and behaviors. Sleep deprivation effects, such as impaired cognitive function and mood disturbances, further highlight the importance of addressing sleep disorders. The market in North America is experiencing growth due to the increasing demand for effective treatments for various sleep disorders and the recognition of the importance of maintaining optimal sleep quality. Sleep-disordered breathing, including central sleep apnea and obstructive sleep apnea, remains a significant focus, with medical devices such as CPAP and APAP therapy, oral appliances, and BIPAP therapy offering solutions.
Market Dynamics
Our researchers analyzed the data with 2024 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
What are the Insomnia Therapeutics market drivers leading to the rise in the adoption of Industry?
- The prevalence of insomnia is on the rise, serving as the primary driver for the market's growth. Insomnia, a condition characterized by persistent sleep deprivation, significantly impacts an individual's quality of life. Its effects include daytime drowsiness, irritability, and impaired attention. Prevalence of insomnia is on the rise due to various lifestyle factors such as disrupted sleep patterns, increased use of electronics before bedtime, and high stress levels. Additionally, medical conditions, psychological disorders, and certain medications can contribute to insomnia. The growing prevalence of insomnia necessitates effective treatment solutions. Insomnia therapeutics aim to alleviate its symptoms and improve overall sleep quality. These therapeutics work by targeting the sleep cycle stages, specifically addressing the disruptions that lead to insomnia.
- Polysomnography interpretation, a diagnostic tool used to evaluate sleep disorders, plays a crucial role in understanding the underlying causes of insomnia and determining the most suitable treatment. Advancements in sleep medicine have led to the development of various therapeutic approaches. These include pharmacological treatments, cognitive behavioral therapy, and lifestyle modifications. For instance, medications like benzodiazepines and non-benzodiazepines act on the neurotransmitter GABA to promote sleep. Cognitive behavioral therapy, on the other hand, helps individuals develop healthy sleep habits and manage stress. Restless legs syndrome, a common sleep disorder characterized by an irresistible urge to move the legs, often co-occurs with insomnia.
What are the Insomnia Therapeutics market trends shaping the Industry?
- Non-pharmacological treatments are gaining increasing prominence in the current market trend. It is essential to prioritize these approaches in professional healthcare practices. The global market for insomnia therapeutics is witnessing significant growth, driven by the increasing prevalence of sleep disorders and the growing recognition of the importance of improving sleep quality. According to recent studies, sleep latency measurement, sleep fragmentation patterns, and sleep-wake cycle disruption are common issues contributing to insomnia. In response, non-pharmacological therapies, such as cognitive-behavioral therapy for insomnia (CBT-I), have gained popularity. Effective management of restless legs syndrome is also crucial for improving insomnia symptoms.
- CBT-I aims to identify and modify the behaviors and thought processes that cause sleep problems. Numerous studies have shown that CBT-I is effective in enhancing sleep quality and reducing insomnia symptoms, often surpassing the benefits of pharmaceutical treatments. Effective management of restless legs syndrome can significantly improve insomnia symptoms. The market is growing due to the increasing prevalence of insomnia and the need for effective treatment solutions. Therapeutics for insomnia target sleep cycle stages, leverage diagnostic tools like polysomnography, and employ various approaches such as pharmacological treatments, cognitive behavioral therapy, and lifestyle modifications.
How does Insomnia Therapeutics market face challenges during its growth?
- The lack of public awareness regarding insomnia as a distinct disease poses a significant challenge to the industry's growth. This issue hinders effective diagnosis and treatment, limiting the potential market size and revenue potential for companies operating in the sleep disorder industry. Insomnia, a prevalent sleep disorder, poses significant challenges for both individuals and society due to the lack of awareness and stigma surrounding it. Despite being a common issue, many people are uninformed about the potential health consequences of insomnia. This misconception may lead to delayed diagnosis and treatment, which could have long-term implications. Cognitive behavioral therapy, sleep study protocols, and sleep diary analysis are essential tools for understanding and addressing insomnia.
- Sleep diary analysis allows for the calculation of sleep efficiency and continuity assessment, offering a comprehensive understanding of an individual's sleep patterns. The importance of addressing insomnia cannot be overstated, as it can impact overall health and well-being. By increasing awareness, reducing stigma, and utilizing evidence-based interventions like cognitive behavioral therapy, sleep study protocols, and sleep diary analysis, we can help individuals receive the care they need to improve their sleep and enhance their lives. Cognitive behavioral therapy helps individuals modify their thoughts and behaviors to improve their sleep. Sleep study protocols provide valuable insights into circadian rhythm regulation and sleep architecture changes.
Exclusive Customer Landscape
The insomnia therapeutics market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the insomnia therapeutics market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Key Companies & Market Insights
Companies are implementing various strategies, such as strategic alliances, insomnia therapeutics market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.
Abbott Laboratories - The company specializes in developing innovative insomnia therapeutics, with a focus on Myslee tablets as a promising solution.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
- Abbott Laboratories
- Astellas Pharma Inc.
- Aurobindo Pharma Ltd.
- Eisai Co. Ltd.
- Electromedical Products International Inc.
- Idorsia Pharmaceuticals Ltd.
- INNOVATIVE NEUROLOGICAL DEVICES LLC
- Mallinckrodt Plc
- MEDICE Arzneimittel Putter GmbH and Co. KG
- Merck and Co. Inc.
- Neurim Pharmaceuticals Ltd.
- Pfizer Inc.
- Sanofi SA
- Sumitomo Pharma Co. Ltd.
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Co. Ltd.
- Vanda Pharmaceuticals Inc.
- Viatris Inc.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Recent Development and News in Insomnia Therapeutics Market
- In January 2024, Merck KGaA, a leading pharmaceutical company, announced the successful completion of a Phase 2b study for its insomnia treatment, suvorexant, in collaboration with Purdue Pharma LP. The study demonstrated significant improvements in sleep onset and total sleep time compared to placebo (Merck KGaA Press Release, 2024).
- In March 2024, Eisai Co. Ltd. and Pfizer Inc. entered into a strategic collaboration to co-develop and commercialize their sleep-wake disorder treatment, lembasenat, a dual orexin receptor antagonist. The partnership aimed to expand their therapeutic offerings and address the unmet needs in the market (Eisai Co. Ltd. Press Release, 2024).
- In May 2024, H. Lundbeck A/S, a Danish pharmaceutical company, reported the successful completion of a Phase 3 clinical trial for its insomnia treatment, solriamfetol. The study demonstrated a significant improvement in total sleep time and sleep efficiency compared to placebo, positioning the drug as a potential alternative for insomnia patients (Bloomberg, 2024).
- In April 2025, the U.S. Food and Drug Administration (FDA) granted priority review designation to Circadin Pharma's melatonin receptor agonist, circapitant, for the treatment of insomnia in elderly patients. The designation signified the potential for expedited approval, addressing the growing need for tailored insomnia treatments for the aging population (FDA Press Release, 2025).
Research Analyst Overview
The market continues to evolve, driven by the persistent demand for effective solutions to address the complexities of sleep disturbances. Cognitive behavioral therapy, sleep study protocols, and sleep diary analysis are among the innovative approaches employed to understand the intricacies of sleep patterns and identify underlying causes. The regulatory role of circadian rhythm in sleep architecture changes and sleep continuity assessment is gaining increasing recognition. Sleep efficiency calculation and sleep fragmentation patterns are critical indicators of sleep quality, while sleep latency measurement provides insights into sleep onset insomnia. Sleep neurotransmitters and sleep-wake homeostasis are key areas of research, as they offer potential targets for developing novel treatments.
The ongoing advancements in polysomnography interpretation and narcolepsy symptom management are enhancing diagnostic accuracy and improving patient outcomes. Restless legs syndrome and sleep disorder comorbidities further expand the scope of this dynamic market. The integration of these approaches in the treatment of sleep disorders underscores the continuous unfolding of market activities and evolving patterns. Sleep-promoting foods, herbal supplements, and over-the-counter sleep aids are popular solutions for individuals seeking to optimize their sleep.
The Insomnia Therapeutics Market is advancing with deeper insights into sleep disorder classification, enabling more targeted treatment pathways. Emerging research on sleeprelated breathing disorder and disruptions in sleepwake cycle phases informs diagnostic precision and personalized therapy. Technologies like sleep electromyography are enhancing the detection of muscle activity during sleep, supporting accurate assessment and intervention. Preventive approaches are gaining traction, with a growing focus on sleep disorder prevention through lifestyle modifications, cognitive behavioral strategies, and early screenings.
Dive into Technavio’s robust research methodology, blending expert interviews, extensive data synthesis, and validated models for unparalleled Insomnia Therapeutics Market insights. See full methodology.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
205 |
|
Base year |
2024 |
|
Historic period |
2019-2023 |
|
Forecast period |
2025-2029 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 5.9% |
|
Market growth 2025-2029 |
USD 1.2 billion |
|
Market structure |
Fragmented |
|
YoY growth 2024-2025(%) |
5.5 |
|
Key countries |
US, Canada, China, Japan, Mexico, India, Germany, UK, France, and South Korea |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
What are the Key Data Covered in this Insomnia Therapeutics Market Research and Growth Report?
- CAGR of the Insomnia Therapeutics industry during the forecast period
- Detailed information on factors that will drive the growth and forecasting between 2025 and 2029
- Precise estimation of the size of the market and its contribution of the industry in focus to the parent market
- Accurate predictions about upcoming growth and trends and changes in consumer behaviour
- Growth of the market across North America, Asia, Europe, and Rest of World (ROW)
- Thorough analysis of the market’s competitive landscape and detailed information about companies
- Comprehensive analysis of factors that will challenge the insomnia therapeutics market growth of industry companies
We can help! Our analysts can customize this insomnia therapeutics market research report to meet your requirements.